헤테로 리서치 파운데이션 / 인도 안드레 패드레시 *** *** 하이데라바드 사나뜨 나갈 산업단지 헤테로 코퍼레이트 *-*-A* 헤테로 드럭스 리미티드
대리인 / 주소
특허법인 플러스
심사청구여부
있음 (2012-02-13)
심사진행상태
등록결정(재심사후)
법적상태
소멸
초록
본 발명은 새로운 루페올-형 트리테르펜 유도체(LUPEOL-TYPE TRITERPENE DERIVATIVES) 및 이의 화합물, 바이러스성 질병, 특히 인체 면역결핍바이러스(Human immunodeficiency virus, HIV) 매개 질병에 유용한 조성물에 관한 것이다.
대표청구항▼
하기와 같이 구성된 그룹으로부터 선택되는 화합물 및 이의 약제학적으로 허용가능한 염.4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-2,2-디메틸-3-(피페리딘-1-카르보닐)시클로부틸카르바모일)-5a,5b,8,8,11a-펜타메틸-1-(프로프-1-엔-2-일)이코사히드로-1H-시클로펜타[a]크라이 센-9-일옥시)-2,2-디메틸-4-옥소부타노산 {4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-2,2-dimethyl-3-(p
하기와 같이 구성된 그룹으로부터 선택되는 화합물 및 이의 약제학적으로 허용가능한 염.4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-2,2-디메틸-3-(피페리딘-1-카르보닐)시클로부틸카르바모일)-5a,5b,8,8,11a-펜타메틸-1-(프로프-1-엔-2-일)이코사히드로-1H-시클로펜타[a]크라이 센-9-일옥시)-2,2-디메틸-4-옥소부타노산 {4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-2,2-dimethyl-3-(piperidine-1-carbonyl)cyclobutylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yloxy)-2,2-dimethyl-4-oxobutanoic acid },(1S,3R)-3-(((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-2,2-디메틸-3-(피페리딘-1-카르보닐)시클로부틸카르바모일)-5a,5b,8,8,11a-펜타메틸-1-(프로프-1-엔-2-일)이코사히드로-1H-시클로펜타[a]크라이센-9-일옥시)카르보닐)-2,2-디메틸시클로부탄카르복실산 {(1S,3R)-3-(((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-2,2-dimethyl-3-(piperidine-1-carbonyl)cyclobutylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yloxy)carbonyl)-2,2-dimethylcyclobutanecarboxylic acid },(1S,3R)-3-(((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1S,3R)-2,2-디메틸-3-(모르폴린-4-카르보닐)시클로부틸카르바모일)-5a,5b,8,8,11a-펜타메틸-1-(프로프-1-엔-2-일)이코사히드로-1H-시클로펜타[a]크라이센-9-일옥시)카르보닐)-2,2-디메틸시클로부탄카르복실산 {(1S,3R)-3-(((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1S,3R)-2,2-dimethyl-3-(morpholine-4-carbonyl)cyclobutylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yloxy)carbonyl)-2,2-dimethylcyclobutanecarboxylic acid },4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1S,3R)-3-(4-에틸피페라진-1-카르보닐)-2,2-디메틸시클로부틸카르바모일)-5a,5b,8,8,11a-펜타메틸-1-(프로프-1-엔-2-일)이코사히드로-1H-시클로펜타[a]크라이센-9-일옥시)-2,2-디메틸-4-옥소부타노산 {4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1S,3R)-3-(4-ethylpiperazine-1-carbonyl)-2,2-dimethylcyclobutylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]ch rysen-9-yloxy)-2,2-dimethyl-4-oxobutanoic acid },4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-3-(4-에틸피페라진-1-카르보닐)-2,2-디메틸시클로부틸카르바모일)-5a,5b,8,8,11a-펜타메틸-1-(프로프-1-엔-2-일)이코사히드로-1H-시클로펜타[a]크라이센-9-일옥시)-2,2-디메틸-4-옥소부타노산 {4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1R,3S)-3-(4-ethylpiperazine-1-carbonyl)-2,2-dimethylcyclobutylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-yloxy)-2,2-dimethyl-4-oxobutanoic acid }
※ AI-Helper는 부적절한 답변을 할 수 있습니다.